Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Daniel Peters, Diana Abbott, Jingjing Zhang, Jacob Fang, Zenggang Pan, Jeffrey Schowinsky, Jonathan Gutman, Andrew Kent, Mathew Angelos, Christine McMahon, Maria Amaya, Marc Schwartz, Wei Xie, Jonathan Galeotti, Jill Buss, Ann-Kathrin Eisfeld, Curtis Lachowiez, Joshua Zeidner, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2025-3377

Published: 2025

Journal Articles

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Virginia Tan, Jean Sabile, Amrita Desai, Arpita Gandhi, Jennifer Saultz, Gabrielle Meyers, Laura Newell, Rachel Cook, Elie Traer, Curtis Lachowiez, Ronan Swords, Richard Maziarz, Theodore Braun, Brandon Hayes-Lattin, Jessica Leonard

Blood (2025) 146 (Supplement 1): 3372.

https://doi.org/10.1182/blood-2025-3372

Published: 2025

Journal Articles

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Blood (2025) 146 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2025-3354

Published: 2025

Journal Articles

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Howard Chang, Staci Williamson, Daniel Chandra, Andy Chen, Rachel Cook, Amrita Desai, Arpita Gandhi, Brandon Hayes-Lattin, Curtis Lachowiez, Jessica Leonard, Richard Maziarz, Laura Newell, Jennifer Saultz, Ronan Swords, Elie Traer, Gabrielle Meyers

Blood (2025) 146 (Supplement 1): 6085.

https://doi.org/10.1182/blood-2025-6085

Published: 2025

Journal Articles

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Guillermo Montalban-Bravo, Courtney DiNardo, Peter Greenberg, Richard Stone, Eric Padron, David Sallman, Curtis Lachowiez, Jonathan Abbas, Abhishek Mangaonkar, Mrinal Patnaik, Marissa Timothy, Alonzo Martinez, Ewelina Morawa, Brandon Turunen, Philip Vickers, Sergio Santillana

Blood (2025) 146 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2025-3874

Published: 2025

Journal Articles

IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease

Blood (2025) 146 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2025-3169

Published: 2025

Journal Articles

A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia

Christopher Eide, Stephen Kurtz, Andy Kaempf, Nicola Long, Alexandria Miller, Daniel Bottomly, Shannon McWeeney, Curtis Lachowiez, Sudarshan Anand, Stanley Ng, Jean Wang, John Dick, Jeffrey Tyner

Blood (2025) 146 (Supplement 1): 657.

https://doi.org/10.1182/blood-2025-657

Published: 2025

Journal Articles

Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial

Blood (2025) 146 (Supplement 1): 635.

https://doi.org/10.1182/blood-2025-635

Published: 2025

Journal Articles

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

Uma Borate, Shivani Handa, Kaitlyn Dvorak-Kornaus, Ronan Swords, Curtis Lachowiez, Qiuhong Zhao, Yazan Madanat

Blood (2025) 146 (Supplement 1): 238.

https://doi.org/10.1182/blood-2025-238

Published: 2025

Journal Articles

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Blood (2025) 146 (Supplement 1): 1083.

https://doi.org/10.1182/blood-2025-1083

Published: 2025

Journal Articles

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Blood (2025) 146 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2025-4252

Published: 2025

Journal Articles

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

Curtis Lachowiez, Andy Kaempf, Carolyn Lehn, Tara Lundberg Williams, Gabriella Sheldon, Jessica Leonard, Gabrielle Meyers, Arpita Gandhi, Jennifer Saultz, Brandon Hayes-Lattin, Richard Maziarz, Rachel Cook, Ronan Swords, Gordon Mills, Theodore Braun

Blood (2025) 146 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2025-1649

Published: 2025

Journal Articles

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Blood (2025) 146 (Supplement 1): 7744.

https://doi.org/10.1182/blood-2025-7744

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Blood (2025) 146 (Supplement 1): 5278.

https://doi.org/10.1182/blood-2025-5278

Published: 2025

Journal Articles

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 701.

https://doi.org/10.1182/blood-2021-150457

Published: 2021

Journal Articles

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Curtis Lachowiez, Courtney D. DiNardo, Kiyomi Morita, Ken Furudate, Feng Wang, Tomoyuki Tanaka, Sa A Wang, Tapan M. Kadia, Naval Daver, Nicholas J. Short, Joseph D. Khoury, Keyur Patel, L. Jeffrey Medeiros, Marina Konopleva, Farhad Ravandi, Koichi Takahashi, Sanam Loghavi

Blood (2021) 138 (Supplement 1): 607.

https://doi.org/10.1182/blood-2021-148971

Published: 2021

Journal Articles

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-134300

Published: 2020

Journal Articles

Identifying Unexpected Inherited Marrow Failure Syndromes in Adults Presenting with Aplastic Anemia, MDS or Solid Tumors

Curtis Lachowiez, MD, Gabrielle Meyers, MD

Blood (2016) 128 (22): 5071.

https://doi.org/10.1182/blood.V128.22.5071.5071

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease

A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia

Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Identifying Unexpected Inherited Marrow Failure Syndromes in Adults Presenting with Aplastic Anemia, MDS or Solid Tumors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only